Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Thermo Fisher Scientific Inc. (NYSE:TMO) has earned a consensus recommendation of “Moderate Buy” from the twenty analysts that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, fifteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $650.41.

TMO has been the topic of a number of research reports. Raymond James lifted their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Barclays cut their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Wells Fargo & Company started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 price target on the stock. Finally, UBS Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th.

Thermo Fisher Scientific Stock Up 0.7 %

Thermo Fisher Scientific stock opened at $618.57 on Tuesday. The company’s 50 day simple moving average is $607.53 and its 200 day simple moving average is $582.11. Thermo Fisher Scientific has a fifty-two week low of $415.60 and a fifty-two week high of $627.88. The firm has a market capitalization of $236.29 billion, a price-to-earnings ratio of 39.68, a PEG ratio of 3.90 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same quarter last year, the firm earned $5.15 EPS. Thermo Fisher Scientific’s quarterly revenue was down 1.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Thermo Fisher Scientific will post 21.72 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,860,920.55. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,084 shares of company stock valued at $14,094,292. 0.34% of the stock is owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mattson Financial Services LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth about $1,078,000. Centaurus Financial Inc. lifted its position in Thermo Fisher Scientific by 3.3% during the second quarter. Centaurus Financial Inc. now owns 6,283 shares of the medical research company’s stock worth $3,475,000 after purchasing an additional 201 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Thermo Fisher Scientific by 0.4% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 68,321 shares of the medical research company’s stock worth $37,782,000 after purchasing an additional 264 shares during the period. Heritage Wealth Management Inc. bought a new position in shares of Thermo Fisher Scientific in the second quarter worth about $334,000. Finally, Sanctuary Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth about $31,573,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.